Gilead Sciences biotechnologist has obtained hopeful test results with his corona drug remdesivir.
According to the company, clinical trials show that the mortality risk of corona patients has decreased by 62 percent after treatment with remdesivir compared to standard care.
Gilead, USA, further reported that the mortality rate of patients treated with remdesivir on day fourteen of the study was 7.6 percent.
That was 12.5 percent of patients who were not given the drug.
In addition, after two weeks, nearly three-quarters of corona patients with remdesivir had recovered, compared to 59 percent of patients who received regular care.
The US authorities accelerated the use of Remdesivir in May to treat critically ill corona patients. The drug has also been made available in other countries.